About BiomeSense
BiomeSense is a Healthcare company based in Chicago (United States) founded in 2018 by Jack Gilbert, Savas Tay, and Kevin Honaker. AI-enabled platform for microbiome data generation and analysis is developed. BiomeSense has raised $8.43 million across 5 funding rounds from investors including HHS, Bluestein Ventures and Harvest Ridge Capital. The company has 9 employees. Its chief executive, as recorded, is Kevin Honaker. BiomeSense offers products and services including GutLab Technology, MetaBiome AI Platform, and Full Laboratory Services. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its competitors include Seed, Omega Therapeutics and Azitra; 3 of its 3 listed competitors have raised funding.
Company details
Developer of AI-enabled technology platform for microbiome data generation and analysis. The company provides continuous, comprehensive microbiome data and AI-enabled bioinformatics. It offers GutLab technology for continuous tracking of the patients gut microbiome throughout the treatment journey. The companys MetaBiome AI Platform transforms and analyzes the data using time-series analyses, enabling identification of clinically-relevant shifts and patterns. The platform unlocks host-microbiome interactions, such as a signature suggesting the gut microbiome may be a biomarker for active tumor burden. The company partners with scientists, institutions, and companies conducting clinical research into the gut microbiome, with a focus on personalized biomarker discovery and product development.
- Headquarters Chicago, United States
- Employees 9
- Founders Jack Gilbert, Savas Tay, Kevin Honaker
- SectorsHealthcare
- Email••••••••
- Website biomesense.com
- Social LinkedIn X Facebook
- Total Equity Funding$8.43M (USD)
in 5 rounds
- Latest Funding Round$6.18M (USD), Seed
Feb 2023
- InvestorsHHS
& 6 more
- Employee Count9
Products & Services of BiomeSense
BiomeSense offers a comprehensive portfolio of products and services, including GutLab Technology, MetaBiome AI Platform, and Full Laboratory Services.
Enables continuous at-home gut microbiome monitoring for research.
Analyzes microbiome data to identify patterns and clinical insights.
Offers sequencing and support for microbiome data generation.
Funding Insights of BiomeSense
BiomeSense has successfully raised a total of $8.43M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $6.18 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.43M
- Total Rounds 5
- Last Round Seed — $6.18M
- First Round $250,000
(Jun 2019)
- Investors Count 7
All 5 funding rounds of BiomeSense with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $6.18M | Seed | – | Bluestein Ventures | |
| Jun 2021 | $294,404 | Grant | – | – | |
| Jan 2021 | $255,658 | Grant | – | – | |
| Oct 2019 | $2M | Seed | – | BioX Clan | |
| Jun 2019 | $250,000 | Seed | – | IndieBio | – |
7 investors in total: 7 institutional.
Investors in BiomeSense
BiomeSense has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Bluestein Ventures and Harvest Ridge Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are provided in the food industry. | bluesteinventures.com | Chicago, United States | ||
| harvestridgecapital.com | ||||
Venture capital and accelerator services are provided across multiple sectors. | sosv.com | Cork, Ireland | ||
| bioxclan.com | ||||
Biotech startups are accelerated through IndieBio's focused programs. | indiebio.co | San Francisco, United States | ||
Seerave Foundation is focused on microbiome and cancer research. | 2015 | seerave.org | St. Helier, Jersey, Channel Islands | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for BiomeSense
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BiomeSense
3 people are tracked at BiomeSense (3 in leadership); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Jack Gilbert | Co-Founder | Leadership |
Savas Tay | Co-Founder | Leadership |
Kevin Honaker | Co-Founder & CEO | Leadership |
Complete people profiles for BiomeSense
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BiomeSense
3 dated milestones of BiomeSense across 5 years, from founding to its latest funding, stage changes and deals.
- Founded BiomeSense is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Seed, of $6.2M.
Competitors of BiomeSense
BiomeSense has 3 listed competitors in our database, 3 of them funded. They include Seed, Omega Therapeutics and Azitra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| seed.com | 2016 | Los Angeles, United States | $40.62M | Synbiotics are developed for simulating the gut microbiome. | ||
| omegatherapeutics.com | 2016 | Cambridge, United States | $211M | 93 | Platform for human genome study is provided for precision medicine. | |
| azitrainc.com | 2014 | Farmington, United States | $37.4M | 17 | Microbiome-based therapeutics for skin conditions like eczema are developed. |
Detailed competitors of BiomeSense
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as BiomeSense (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biomesense
Complete news archive for BiomeSense
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BiomeSense
BiomeSense was founded in 2018 and raised its 1st funding round 1 year after it was founded.
BiomeSense is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Kevin Honaker is the CEO of BiomeSense, as recorded in our data. They have also founded this company.
BiomeSense is a funded company, having raised a total of $8.43M across 5 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Jun 2019.
BiomeSense has 9 employees.
Developer of AI-enabled technology platform for microbiome data generation and analysis. The company provides continuous, comprehensive microbiome data and AI-enabled bioinformatics. It offers GutLab technology for continuous tracking of the patients gut microbiome throughout the treatment journey. The companys MetaBiome AI Platform transforms and analyzes the data using time-series analyses, enabling identification of clinically-relevant shifts and patterns. The platform unlocks host-microbiome interactions, such as a signature suggesting the gut microbiome may be a biomarker for active tumor burden. The company partners with scientists, institutions, and companies conducting clinical research into the gut microbiome, with a focus on personalized biomarker discovery and product development.
BiomeSense's top competitors include Omega Therapeutics, Azitra and Seed.
BiomeSense offers GutLab Technology, MetaBiome AI Platform, and Full Laboratory Services.
BiomeSense has 7 investors. Key investors include HHS, Bluestein Ventures, Harvest Ridge Capital, Seerave Foundation, and SOSV.